论文部分内容阅读
目的探讨趋化因子CCL21和CXCL12及其相应受体在非霍奇金淋巴瘤(NHL)中的表达及临床意义。方法回顾性分析68例NHL患者、34例淋巴结反应性增生患者及28例正常健康人群的临床资料,采用免疫组化法检测淋巴组织中CCL21、CXCL12及其受体的表达,ELISA法分析血浆中CCL21和CXCL12的表达,流式细胞术检测骨髓细胞中CXCR4、CCR7的表达。结果 CXCR4和CCL21在NHL多部位发生、最大标准摄取值(SUVmax)>9及侵袭性淋巴瘤中高表达;CXCL12和CCR7分别在SUVmax>9和侵袭性淋巴瘤中高表达。NHL患者化疗前CCL21、CXCL12、CXCR4和CCR7表达均高于淋巴结反应性增生患者和正常健康人群(P<0.05),而化疗后都有不同程度的降低。结论趋化因子CCL21和CXCL12及其受体表达与NHL侵袭、进展及预后密切相关。
Objective To investigate the expression and clinical significance of chemokines CCL21 and CXCL12 and their related receptors in non-Hodgkin’s lymphoma (NHL). Methods The clinical data of 68 patients with NHL, 34 patients with reactive hyperplasia of lymph nodes and 28 healthy controls were retrospectively analyzed. The expressions of CCL21, CXCL12 and their receptors in lymphoid tissue were detected by immunohistochemistry, CCL21 and CXCL12 expression in bone marrow cells by flow cytometry CXCR4, CCR7 expression. Results CXCR4 and CCL21 were found in multiple sites of NHL, with SUVmax> 9 and in aggressive lymphoma. CXCL12 and CCR7 were highly expressed in SUVmax> 9 and invasive lymphoma, respectively. The expression of CCL21, CXCL12, CXCR4 and CCR7 in patients with NHL before chemotherapy was significantly higher than that in patients with lymph node-reactive hyperplasia and normal healthy (P <0.05), and all were decreased to some extent after chemotherapy. Conclusion The expression of chemokines CCL21 and CXCL12 and their receptors are closely related to the invasion, progression and prognosis of NHL.